Leibniz-Institute for Natural Product Research and Infection Biology (HKI), Beutenbergstrasse 11a, 07745, Jena, Germany.
Amino Acids. 2013 Apr;44(4):1225-31. doi: 10.1007/s00726-013-1459-3. Epub 2013 Jan 11.
In this study, a precise and reliable ultra-high performance liquid chromatography (UHPLC) method for the simultaneous determination of non-canonical (norvaline and norleucine) and standard amino acids (aspartic acid, glutamic acid, serine, histidine, glycine, threonine, arginine, tyrosine, methionine, valine, phenylalanine, isoleucine, leucine) in biopharmaceutical-related fermentation processes was established. After pre-column derivatization with ortho-phthaldialdehyde and 2-mercaptoethanol, the derivatives were separated on a sub-2 μm particle C18 reverse-phase column. Identification and quantification of amino acids were carried out by fluorescence detection. To test method feasibility on standard HPLC instruments, the assay was properly transferred to a core-shell particle C18 reverse-phase column. The limits of detection showed excellent sensitivity by values from 0.06 to 0.17 pmol per injection and limits of quantification between 0.19 and 0.89 pmol. In the present study, the newly established UHPLC method was applied to a recombinant antibody Escherichia coli fermentation process for the analysis of total free amino acids. We were able to specifically detect and quantify the unfavorable amino acids in such complex samples. Since we observed trace amounts of norvaline and norleucine during all fermentation phases, an obligatory process monitoring should be considered to improve quality of recombinant protein drugs in future.
本研究建立了一种用于同时测定生物制药相关发酵过程中非典型(正缬氨酸和正亮氨酸)和标准氨基酸(天冬氨酸、谷氨酸、丝氨酸、组氨酸、甘氨酸、苏氨酸、精氨酸、酪氨酸、甲硫氨酸、缬氨酸、苯丙氨酸、异亮氨酸、亮氨酸)的精确可靠的超高效液相色谱(UHPLC)方法。经邻苯二甲醛和 2-巯基乙醇柱前衍生后,用亚 2μm 粒径 C18 反相柱分离衍生物。采用荧光检测进行氨基酸的鉴定和定量。为了在标准 HPLC 仪器上测试方法的可行性,将该方法适当转移到核壳型 C18 反相柱上。检测限通过每次进样的 0.06 至 0.17 pmol 和 0.19 至 0.89 pmol 的值显示出优异的灵敏度。在本研究中,新建立的 UHPLC 方法应用于重组抗体大肠杆菌发酵过程,用于分析总游离氨基酸。我们能够在如此复杂的样品中特异性地检测和定量不利的氨基酸。由于在所有发酵阶段都观察到痕量的正缬氨酸和正亮氨酸,因此应考虑进行强制性的过程监测,以在未来提高重组蛋白药物的质量。